Anavex to Present at American Epilepsy Society Annual Meeting ANAVEX 2-73 Demonstrates Anti-Seizure Effects in Well Established Preclinical Seizure Models

NEW YORK, NY – November 19, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the presentation of preclinical epilepsy data at the upcoming American Epilepsy Society…